Page last updated: 2024-12-07
cryptating agent 221
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
cryptating agent 221: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 123438 |
SCHEMBL ID | 25928 |
MeSH ID | M0151665 |
Synonyms (32)
Synonym |
---|
4,7,13,16,21-pentaoxa-1,10-diazabicyclo[8.8.5]tricosane |
4,7,13,16,21-pentaoxa-1,10-diazabicyclo[8.8.5.]tricosane |
nsc321059 |
31364-42-8 |
nsc-321059 |
kryptofix 221 |
4,7,13,16,21-pentaoxa-1,10-diazabicyclo[8.8.5]tricosane, 98% |
FT-0660588 |
AKOS015916737 |
einecs 250-592-1 |
nsc 321059 |
4,7,13,16,21-pentaoxa-1,10-diazabicyclo(8.8.5)tricosane |
cryptand-221 |
cryptating agent 221 |
cryptand 221 |
SCHEMBL25928 |
kryptofix(r) 221 |
4,7,13,16,21-pentaoxa-1,10-diazabicyclo[8.8.5]tricosane # |
kryptofix-221 |
HDLXPNDSLDLJHF-UHFFFAOYSA-N |
4,7,16,21-pentaoxa-1,10-diazabicyclo[8.8.5.]tricosane |
mfcd00005108 |
J-200342 |
DTXSID60185286 |
AS-70036 |
kryptofix(r)221 |
BCP14291 |
A875929 |
4,7,13,16,21-pentaoxa-1,10-diazabicyclo-[8.8.5]tricosane |
kryptofix221 |
(4,7,13,16,21-pentaoxa-1,10-diazabicyclo[8.8.5]tricosane) |
AC-37052 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (8)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 2 (25.00) | 18.7374 |
1990's | 4 (50.00) | 18.2507 |
2000's | 2 (25.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.25
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.25) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 8 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |